UA95488C2 - Концентрированный раствор метотрексата для подкожного введения - Google Patents

Концентрированный раствор метотрексата для подкожного введения

Info

Publication number
UA95488C2
UA95488C2 UAA200901346A UAA200901346A UA95488C2 UA 95488 C2 UA95488 C2 UA 95488C2 UA A200901346 A UAA200901346 A UA A200901346A UA A200901346 A UAA200901346 A UA A200901346A UA 95488 C2 UA95488 C2 UA 95488C2
Authority
UA
Ukraine
Prior art keywords
concentrated
ready
carpule
methotrexate solution
subcutaneous introduction
Prior art date
Application number
UAA200901346A
Other languages
English (en)
Ukrainian (uk)
Inventor
Гейнер Вилль
Original Assignee
Медак Гезельшафт Фюр Клинише Шпециальпрепарате Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38640096&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95488(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Медак Гезельшафт Фюр Клинише Шпециальпрепарате Мбх filed Critical Медак Гезельшафт Фюр Клинише Шпециальпрепарате Мбх
Publication of UA95488C2 publication Critical patent/UA95488C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Описаны концентрированные растворы метотрексата, пригодные для применения активного вещества при производстве лекарственного средства, которое вводят подкожно, для лечения воспалительных аутоиммунных заболеваний. Метотрексат добавляют к фармацевтически приемлемому растворителю при концентрации 50 мг/мл. Данное изобретение также относится к готовому шприцу и карпуле, содержащей такой фармацевтический раствор, а также к ручке-иньектору, которая содержит такую карпулу и/или готовый шприц.
UAA200901346A 2006-07-21 2007-07-20 Концентрированный раствор метотрексата для подкожного введения UA95488C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006033837A DE102006033837A1 (de) 2006-07-21 2006-07-21 Konzentrierte Methotrexat-Lösungen

Publications (1)

Publication Number Publication Date
UA95488C2 true UA95488C2 (ru) 2011-08-10

Family

ID=38640096

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200901346A UA95488C2 (ru) 2006-07-21 2007-07-20 Концентрированный раствор метотрексата для подкожного введения

Country Status (22)

Country Link
US (7) US8664231B2 (ru)
EP (2) EP2046332B1 (ru)
JP (1) JP5683810B2 (ru)
KR (1) KR101260554B1 (ru)
AT (2) ATE491455T1 (ru)
AU (1) AU2007276387B2 (ru)
BR (1) BRPI0715433A2 (ru)
CA (2) CA2869671A1 (ru)
CY (1) CY1111159T1 (ru)
DE (3) DE102006033837A1 (ru)
DK (1) DK2046332T3 (ru)
ES (1) ES2355399T3 (ru)
HR (1) HRP20110148T1 (ru)
ME (1) ME01940B (ru)
MX (1) MX2009000812A (ru)
PL (1) PL2046332T3 (ru)
PT (1) PT2046332E (ru)
RS (1) RS51688B (ru)
RU (1) RU2403044C1 (ru)
SI (1) SI2046332T1 (ru)
UA (1) UA95488C2 (ru)
WO (1) WO2008009476A2 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040103930A (ko) 2002-02-11 2004-12-09 앤태어스 파머, 인코퍼레이티드 피내 주사기
ES2716135T5 (es) 2005-01-24 2023-06-15 Antares Pharma Inc Inyector de chorro asistido por aguja con jeringa precargada
WO2007131025A1 (en) 2006-05-03 2007-11-15 Antares Pharma, Inc. Injector with adjustable dosing
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
DE102006033837A1 (de) * 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen
CN101605547A (zh) * 2006-11-21 2009-12-16 卡罗拜奥斯制药公司 使用gm-csf拮抗剂治疗慢性炎症疾病的方法
US8814834B2 (en) 2008-03-10 2014-08-26 Antares Pharma, Inc. Injector safety device
ES2738539T3 (es) 2008-08-05 2020-01-23 Antares Pharma Inc Inyector de dosis múltiples
JP5732039B2 (ja) 2009-03-20 2015-06-10 アンタレス・ファーマ・インコーポレーテッド 危険有害性薬剤の注入システム
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
PT2822618T (pt) 2012-03-06 2024-03-04 Antares Pharma Inc Seringa pré-cheia com característica de força de rutura
JP6457383B2 (ja) 2012-04-06 2019-01-23 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針支援式ジェット注入投与
WO2013169800A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Injection device with cammed ram assembly
EP2950856B1 (en) 2013-01-29 2023-10-11 Sanofi-Aventis Deutschland GmbH Electronic module and drug delivery device
EP4349383A3 (en) 2013-02-11 2024-06-19 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
CA2905031C (en) 2013-03-11 2018-01-23 Hans PFLAUMER Dosage injector with pinion system
WO2014165136A1 (en) * 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
WO2015147018A1 (ja) * 2014-03-28 2015-10-01 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤
US20150297600A1 (en) * 2014-04-16 2015-10-22 Antares Pharma, Inc. Method Of Achieving Increased Systemic Availability of Methotrexate
WO2015183213A1 (en) 2014-05-28 2015-12-03 Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid
JP2017066073A (ja) * 2015-09-29 2017-04-06 テルモ株式会社 炎症性自己免疫疾患治療用の注射用水性製剤およびその保存方法
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체
GB2591681A (en) * 2018-08-29 2021-08-04 Ftf Pharma Private Ltd Methotrexate pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357971A (en) * 1980-09-19 1982-11-09 Cyberon Corporation Syringe gauging, loading and injection apparatus
US5279586A (en) * 1992-02-04 1994-01-18 Becton, Dickinson And Company Reusable medication delivery pen
EP0768902B1 (en) * 1992-11-19 1998-07-15 Tebro S.A. Disposable auto-injector for prefilled syringes
US5593671A (en) 1994-07-01 1997-01-14 American Cyanamid Company Method of attenuating lung capillary leak in a mammal
US5542934A (en) * 1995-06-02 1996-08-06 Silver; Richard M. Multiple carpule hypodermic syringe
US6544504B1 (en) 1999-07-28 2003-04-08 Schering Corporation Combined use of interleukin 10 and methotrexate for immuno-modulatory therapy
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
US20040176381A1 (en) * 2003-03-06 2004-09-09 Walsh Michael J. Methotrexate compliance packaging
US20050153969A1 (en) * 2004-01-13 2005-07-14 Iomed, Inc. Methods for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicament
DE102006033837A1 (de) 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Konzentrierte Methotrexat-Lösungen

Also Published As

Publication number Publication date
HRP20110148T1 (hr) 2011-03-31
PL2046332T3 (pl) 2011-05-31
KR101260554B1 (ko) 2013-05-06
EP2046332A2 (de) 2009-04-15
AT14872U1 (de) 2016-08-15
CA2869671A1 (en) 2008-01-24
JP5683810B2 (ja) 2015-03-11
CY1111159T1 (el) 2015-06-11
US20170246172A1 (en) 2017-08-31
US20140155405A1 (en) 2014-06-05
EP2292235A3 (de) 2011-06-01
US20200246342A1 (en) 2020-08-06
AU2007276387A2 (en) 2009-04-02
PT2046332E (pt) 2011-02-04
KR20090079876A (ko) 2009-07-22
US8664231B2 (en) 2014-03-04
JP2009544636A (ja) 2009-12-17
WO2008009476A2 (de) 2008-01-24
ATE491455T1 (de) 2011-01-15
EP2046332B1 (de) 2010-12-15
WO2008009476A3 (de) 2008-11-06
AU2007276387B2 (en) 2010-09-30
RU2403044C1 (ru) 2010-11-10
US10610531B2 (en) 2020-04-07
DE102006033837A1 (de) 2008-01-31
US20150164902A1 (en) 2015-06-18
US20190038629A1 (en) 2019-02-07
ME01940B (me) 2011-10-31
MX2009000812A (es) 2009-07-10
CA2659662A1 (en) 2008-01-24
DE502007005972D1 (de) 2011-01-27
US20140179703A1 (en) 2014-06-26
DE202007019703U1 (de) 2015-10-28
SI2046332T1 (sl) 2011-02-28
US20100016326A1 (en) 2010-01-21
CA2659662C (en) 2015-01-20
RS51688B (en) 2011-10-31
DK2046332T3 (da) 2011-03-07
RU2009106053A (ru) 2010-08-27
BRPI0715433A2 (pt) 2013-07-23
AU2007276387A1 (en) 2008-01-24
EP2292235A2 (de) 2011-03-09
ES2355399T3 (es) 2011-03-25
US11944629B2 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
UA95488C2 (ru) Концентрированный раствор метотрексата для подкожного введения
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
EA201270379A1 (ru) Имплантируемое устройство для контролируемой доставки лекарства
NZ599309A (en) Palm activated drug delivery device
GB2440039A (en) Devices, systems and methods for medicament delivery
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
EP2676691A3 (en) Delivery of viscous formulations by needle-free injection
HK1139871A1 (en) Improvements in and relating to medicinal compositions
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
IL291556B2 (en) Methods and compositions for administration of arylsulfatase A to the central nervous system
TW200628182A (en) Injection device for administering a medication liquid
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
EP3970729A3 (en) Methods of administering high concentrations of nitric oxide
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
RU2013150024A (ru) Способы контроля и лечения хронической боли с применением hcg
MX2009013183A (es) Uso de la proteina de fusion taci-ig, tal como atacicept, para la elaboracion de un medicamento para tratar lupus eritematoso.
WO2007084650A3 (en) Single-dose needle-free administration of antithrombotic medications
RU2011139015A (ru) Вызываемая медикаментозными средствами липоатрофия для косметических целей
EA200801259A1 (ru) Способ получения препарата инсулина для перорального применения
CA2496121A1 (en) Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy
MY174442A (en) Treating critically ill patients with intravenous ibuprofen
TW200727928A (en) Method and apparatus for delivering epinephrine
NO20044976L (no) Befruktningshindrende middel av en oljeholdig losning for selv-administrering